Overdose deaths and the COVID‐19 pandemic in British Columbia, Canada H Palis, MA Bélair, K Hu, A Tu, J Buxton, A Slaunwhite Drug and Alcohol Review 41 (4), 912-917, 2022 | 54 | 2022 |
Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed … B Nosyk, A Slaunwhite, K Urbanoski, N Hongdilokkul, H Palis, K Lock, ... BMJ open 11 (6), e048353, 2021 | 54 | 2021 |
Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder H Palis, K Marchand, D Guh, S Brissette, K Lock, S MacDonald, ... Substance abuse treatment, prevention, and policy 12, 1-12, 2017 | 43 | 2017 |
The relationship between sense of community belonging and self-rated mental health among Canadians with mental or substance use disorders H Palis, K Marchand, E Oviedo-Joekes Journal of Mental Health 29 (2), 168-175, 2020 | 35 | 2020 |
Concurrent use of opioids and stimulants and risk of fatal overdose: a cohort study H Palis, C Xavier, S Dobrer, R Desai, K Sedgemore, M Scow, K Lock, ... BMC Public Health 22 (1), 2084, 2022 | 34 | 2022 |
Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods E Oviedo-Joekes, H Palis, D Guh, K Marchand, S Brissette, S Harrison, ... Journal of substance abuse treatment 101, 50-54, 2019 | 34 | 2019 |
Adverse events during treatment induction with injectable diacetylmorphine and hydromorphone for opioid use disorder E Oviedo-Joekes, H Palis, D Guh, DC Marsh, S MacDonald, S Harrison, ... Journal of addiction medicine 13 (5), 354-361, 2019 | 33 | 2019 |
The role of gender in factors associated with addiction treatment satisfaction among long-term opioid users K Marchand, H Palis, D Peng, J Fikowski, S Harrison, P Spittal, ... Journal of addiction medicine 9 (5), 391-398, 2015 | 32 | 2015 |
Risk of cardiovascular diseases in relation to substance use disorders WQ Gan, JA Buxton, FX Scheuermeyer, H Palis, B Zhao, R Desai, ... Drug and alcohol dependence 229, 109132, 2021 | 29 | 2021 |
Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study A Slaunwhite, JE Min, H Palis, K Urbanoski, B Pauly, B Barker, A Crabtree, ... bmj 384, 2024 | 22 | 2024 |
Characteristics and response to treatment among indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of … E Oviedo‐Joekes, H Palis, D Guh, K Marchand, S Brissette, K Lock, ... Drug and alcohol review 37 (1), 137-146, 2018 | 21 | 2018 |
Predictors of treatment allocation guesses in a randomized controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder E Oviedo-Joekes, K Marchand, H Palis, D Guh, S Brissette, K Lock, ... Addiction Research & Theory 25 (4), 263-272, 2017 | 18 | 2017 |
Factors associated with perceived abuse in the health care system among long-term opioid users: a cross-sectional study H Palis, K Marchand, D Peng, J Fikowski, S Harrison, P Spittal, ... Substance use & misuse 51 (6), 763-776, 2016 | 16 | 2016 |
Patient perceptions of prejudice and discrimination by health care providers and its relationship with mental disorders: results from the 2012 Canadian community health-mental … K Marchand, H Palis, E Oviedo-Joekes Community mental health journal 52, 294-301, 2016 | 16 | 2016 |
Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study J Corser, H Palis, M Fleury, J Lamb, K Lock, J McDougall, A Mehta, ... Harm reduction journal 19 (1), 46, 2022 | 15 | 2022 |
Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report H Palis, S MacDonald, J Jun, E Oviedo-Joekes Harm Reduction Journal 18 (1), 57, 2021 | 14 | 2021 |
Self‐managing illicit stimulant use: A qualitative study with patients receiving injectable opioid agonist treatment H Palis, S Harrison, S MacDonald, DC Marsh, MT Schechter, ... Drug and Alcohol Review 39 (7), 914-923, 2020 | 14 | 2020 |
Physician communication in injectable opioid agonist treatment: collecting patient ratings with the communication assessment tool H Palis, K Marchand, S Beaumont, D Guh, S Harrison, S MacDonald, ... Journal of addiction medicine 14 (6), 480-488, 2020 | 14 | 2020 |
The role of gender in suicidal ideation among long-term opioid users K Marchand, H Palis, J Fikowski, S Harrison, P Spittal, MT Schechter, ... The Canadian Journal of Psychiatry 62 (7), 465-472, 2017 | 14 | 2017 |
A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance … K Marchand, H Palis, D Guh, K Lock, S MacDonald, S Brissette, DC Marsh, ... Journal of Substance Abuse Treatment 132, 108512, 2022 | 13 | 2022 |